Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology

Diagnostic Cytopathology

Volumn 38, Issue 5, 2010, Pages 333-336

  Han, Liying ^a   Pansare, Vaishali ^a   Al Abbadi, Mousa ^a   Husain, Mujtaba ^a   Feng, Jining ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Ascites; Effusion cytology; Immunohistochemistry; Ovary; Pancreas; Peritoneal fluid; Pleural fluid

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 1; MUCIN 2; MUCIN 5AC; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NEPHROBLASTOMA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; STAINING; TUMOR GENE; WILMS TUMOR SUSCEPTIBILITY GENE 1;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CYSTADENOCARCINOMA, SEROUS; CYTOLOGICAL TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN 5AC; MUCIN-1; MUCIN-2; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 77951751534     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21202     Document Type: Article

References (12)

1. Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 1987;31:448-452. (Pubitemid 17126855)
2. Sato T, Ohwada A, Miyaji A, Miyazaki R, Suzuki M, Matsumoto T. Immunohistochemistry for the differentiation of peritoneal disseminated carcinoma of unknown origin. Intern Med 2004;43:415-419. (Pubitemid 38842509)
3. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005. (Pubitemid 37297755)
4. Mohiuddin M, Rosato F, Schuricht A, Barbot D, Biermann W, Cantor R. Cancinoma of the pancreas - The Jefferson experience 1975-1988. Eur J Surg Oncol 1994;20:13-20.
5. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, Disaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important? Obstet Gynecol 2003;102:156-161.
6. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002;117:745-750.
7. Zhu W, Michael C. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-375. (Pubitemid 46835030)
8. Giorgadze TA, Peterman H, Baloch ZW, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: An immunohistochemical study with surgical pathology correlation. Cancer 2006;108:186-197. (Pubitemid 43911815)
9. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391-400.
10. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-19.
11. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530. (Pubitemid 26170688)
12. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinoma: A new marker of DPC4 inactivation. Am J Pathol 2000;31:672-677.